GlaxoSmithKline Consumer Healthcare Limited announces results for the second quarter ended September 30, 2018

GlaxoSmithKline Consumer Healthcare Limited announces results for the second quarter ended September 30, 2018 

Revenue growth of 14.4%, PBT growth of 43% 

Gurugram, 01 November 2018: GlaxoSmithKline Consumer Healthcare Limited today declared its financial results for the second quarter ended September 30, 2018. The Revenue for the company recorded a growth of 14.4%. The quarter reported revenue of Rs. 1,272 crore, while the PBT was at Rs. 427 crores, a growth of 43%.  The quarter witnessed a strong double-digit volume growth at 13.7% that is broad based and cuts across portfolio and channels. 

Company’s e-commerce channel continues to grow at an accelerated pace, delivering a healthy growth rate. Rural channel and Modern Trade continued to grow with rural reaching out to over 22,000 villages. 

Commenting on the results, Navneet Saluja, Managing Director, GlaxoSmithKline Consumer Healthcare Limited said, “Our financial performance in the last quarter reflects our commitment towards developing products based on high science.  With initiatives and campaigns such as Horlicks Swasthyan Abhiyaan, Horlicks restage, and launch of Boost “Play the Pros”, we have strengthened our engagement with consumers”. 

“We will continue to drive innovation across our products and campaigns, which will strengthen the trust in our consumers. This in turn will foster further growth in our financial performance and help us maintain leadership in the HFD category”. Mr. Saluja added. 

 Performance Highlights: 

  • Health food drink portfolio continues to be the market leader with 64.2% value share**
  • Base Horlicks witnessed a strong double-digit volume growth
  • Our access agenda continues to gain strength with our HFD distribution reaching 1.81MN in Q2
  • Focused and customised campaigns such as Horlicks Swasthyan Abhiyaan, Horlicks restage, and Boost “Play the Pros” touched the relevant audience group which in turn contributed to our HFD portfolio growth 

**Source: Nielsen, September ‘18 

About GlaxoSmithKline Consumer Healthcare Ltd

GSK Consumer Healthcare Ltd is the category leader in Indian health food drinks industry. Our flagship product Horlicks leads the market, while Boost is among the top three health food drink brands that India prefers. Our manufacturing plants are located in Nabha, Rajahmundry and Sonepat. In India we have an engaged workforce of over 3800 employees. GSK also markets and distributes a range of everyday health products such as Eno, Crocin, Iodex and Sensodyne. Our marketing and distribution network comprises over 800 distributors and a direct coverage of over 8 lakh retail outlets. 

GSK Consumer Healthcare Ltd is an associate of GlaxoSmithKline plc. of U.K, one of world’s largest consumer healthcare companies. We have a heritage that goes back over 160 years. Our purpose is to help more people around the world to do more, feel better and live longer with everyday healthcare products.  Our goal is to build a global, growing business - we call a Fast-Moving Consumer Healthcare (FMCH) company - dedicated to everyday healthcare with all of the scientific expertise and quality guarantees that demands, working at the speed and with the genuine consumer understanding the modern world expects. 

GSK Consumer Healthcare globally owns some of the world’s best loved healthcare brands, successful in over 100 countries. These include Sensodyne, Theraflu, Paradontax, Panadol, Polident, Otrivin, Horlicks and Physiogel 

Media Contacts

Genesis Burson-Marsteller

Rikhil Seth: rikhil.seth@bm.com /+91 9810647600

Harleen Kaur: harleen.kaur@bm.com/+91 9899597987 

GlaxoSmithKline Consumer Healthcare

Deepa Dey: deepa.d.dey@gsk.com

Kinshuk Gupta: kinshuk.x.gupta@gsk.com